Please check your internet connection and try again.
# Potassium Chloride
## Overview
Potassium chloride (KCL) is an essential electrolyte that plays a vital role in cellular function, nerve impulse transmission, and muscle contraction. It is administered to correct or prevent hypokalemia.
## Primary Indications
* Treatment and prevention of hypokalemia.
## Adult Dosing
Dosing is highly individualized based on serum potassium levels, severity of deficiency, and clinical status.
* **Prevention of hypokalemia:** 20-40 mEq per day in divided doses.
* **Treatment of hypokalemia:**
* Mild hypokalemia (serum K 2.5-3.5 mEq/L): 40-100 mEq per day in divided doses.
* Severe hypokalemia (serum K < 2.5 mEq/L): Up to 200 mEq per day, often requiring intravenous administration and careful cardiac monitoring.
**Maximum recommended doses:**
* Oral: Generally not to exceed 200 mEq per day.
* Intravenous: Typically not to exceed 10 mEq/hour in a peripheral line; central line administration may allow for higher rates (e.g., 20-40 mEq/hour) but requires continuous cardiac monitoring and intensive care setting.
Specific dosing regimens may be dictated by local hospital protocols.
## Pediatric Dosing
Dosing is based on age and weight, and often calculated as mEq/kg/day.
* **Prevention of hypokalemia:** 1-2 mEq/kg/day, not to exceed 40 mEq/day.
* **Treatment of hypokalemia:** 2-5 mEq/kg/day in divided doses.
**Maximum recommended doses:** Generally, doses should not exceed 200 mEq per day. Intravenous administration in pediatric patients requires extreme caution and careful monitoring, especially regarding infusion rate.
Exact pediatric dosing may vary and should be guided by specific pediatric protocols and physician orders.
## Dose Adjustments
* **Renal Impairment:** Dose reduction is necessary in patients with impaired renal function due to the risk of hyperkalemia.
* **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes closely.
## Contraindications
* Hyperkalemia.
* Conditions that predispose to hyperkalemia, such as untreated Addison's disease, acute dehydration, extensive tissue injury, or certain medications (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics).
* Certain gastrointestinal conditions (e.g., esophageal obstruction, delayed gastric emptying) may contraindicate solid oral dosage forms.
## Adverse Effects
* **Most common:** Gastrointestinal upset (nausea, vomiting, abdominal pain, diarrhea).
* **Serious:** Hyperkalemia (manifesting as muscle weakness, paresthesias, cardiac arrhythmias, cardiac arrest), cardiac arrhythmias, hypotension, gastrointestinal bleeding, perforation, or obstruction (especially with sustained-release formulations or rapid IV infusion).
## Key Drug Interactions
* **ACE inhibitors and Angiotensin Receptor Blockers (ARBs):** Increased risk of hyperkalemia.
* **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Additive risk of hyperkalemia.
* **NSAIDs:** Can impair renal excretion of potassium, increasing hyperkalemia risk.
* **Digitalis glycosides:** Hyperkalemia can increase the toxicity of digitalis. Hypokalemia can increase digitalis toxicity.
## Monitoring
* **Serum potassium levels:** Frequently monitor serum potassium, especially during initiation of therapy, dose changes, and in patients with renal impairment.
* **Electrocardiogram (ECG):** Essential for patients receiving rapid intravenous potassium infusions or those with severe hypokalemia to detect cardiac abnormalities.
* **Renal function:** Monitor serum creatinine and BUN.
* **Signs and symptoms of hypokalemia and hyperkalemia.**
## Clinical Pearls
* Potassium chloride should always be diluted before intravenous administration.
* Rapid intravenous infusion of potassium is dangerous and should be avoided unless absolutely necessary and under strict monitoring.
* Sustained-release oral formulations may be associated with gastrointestinal adverse effects and should be used with caution.
* Correction of hypokalemia should be gradual.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive guidance. Dosing recommendations can vary based on individual patient factors and local institutional protocols.
